Dataset Information

CircRNAs as promising biomarker in diagnosis of breast cancer: An updated meta-analysis.

ABSTRACT:

Background

Circular RNAs (circRNAs) have been identified to be involved in onset and progression of multiple malignant tumors. The present study aimed to systematically evaluate the diagnostic values of circRNAs in breast cancer.

Methods

The PubMed, Web of Science, Embase, CNKI, and Wanfang online databases were searched for the relevant studies before December 31, 2020. Statistical analysis of the diagnostic tests was performed based on STATA 16.0, Meta-DiSc 1.4, and RevMan 5.3 software. The threshold effect and publication bias were measured by the Spearman correlation and Deeks' funnel plot asymmetry test, respectively.

Results

Twenty-one studies from 13 articles were included in this meta-analysis. The pooled sensitivity and specificity were 0.77 and 0.71, respectively. The pooled positive likelihood ratio (PLR), negative likelihood ratio (NLR), and overall diagnostic odds ratio (DOR) were 2.6, 0.33, and 8, respectively. Furthermore, the area under the summary receiver operator characteristic curve was 0.80. In addition, down-regulated circRNAs achieved a diagnostic performance higher than up-regulated circRNAs, with area under curve (AUC) values of 0.81 and 0.74, respectively. Studies based on tissue samples presented better diagnostic accuracy than those based on plasma samples, with AUC values of 0.80 and 0.67. In addition, two circRNAs, including circ_0001073 and circTADA2A-E5/E6, showed higher diagnostic values, with AUC value of 0.990 and 0.937, respectively. According to the results of meta-regression, the case size (p<0.05) might be the source of the heterogeneity.

Conclusion

CircRNAs exhibited a high diagnostic value for breast cancer and may function as potential diagnostic biomarkers for breast cancer.

SUBMITTER: Chu M

PROVIDER: S-EPMC8418489 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Different epidemiological studies have indicated conflicting information about the association of induced abortion (IA) with breast cancer risk. A recent meta-analysis with prospective evidences did not support the positive association between IA and breast cancer risk. Thus, we in our meta-analysis study have tried to analyze this specific association.We searched all relevant articles from an English-language literature using Pubmed, Embase, and Cochrane databases, until December 10, 2016. All the statistical analyses were performed on case-control studies, using Review Manager Software 5.3 (Cochrane Collaboration, Oxford, UK).Our meta-analysis results based on 25 studies, including 5 studies with Chinese patients, indicated that there was no association of IA with breast cancer (OR = 1.08, 95% CI 0.98-1.19, P = .1). However, significant heterogeneity was observed, and thus further subgroup analyses were conducted. The combined OR of subjects with only 1-time IA was 1.03, 95% CI 0.90 to 1.18, P = .63, while for subjects with 2 or more IAs, it was 1.06, 95% CI 0.86 to 1.30, P = .58. In addition, the ORs of subjects, with 1st IA age either less than 30 or older than 30, were 1.05, 95% CI 0.88 to 1.26, P = .59, and 1.18, 95% CI 0.93 to 1.49, P = .17, respectively. These observations indicated that number of IAs and the age of 1st IA were not associated with breast cancer risk. Due to lack of dose-response relationships, it is difficult to say if number of IAs contributed into statistical heterogeneity. But after subgroup analysis, the age at the 1st IA appeared to impact the statistical heterogeneity. The different reproductive history appears to account for the high heterogeneity among individual studies. Also analysis of nulliparous women showed no significant difference in the association of IA and breast cancer (OR = 1.02, 95% CI 0.86-1.21, P = .85). However, parous women had higher IA rate in case group than control group (OR = 1.11, 95% CI 1.02-1.20, P = .01). Ethnicities might also result in high heterogeneity; thus, we conducted subgroup analyses on Chinese subjects, importantly, with 5 studies having Chinese patients, and did not observe any difference in the incidence of IA and its association with breast cancer between case and control groups (OR = 1.05, 95% CI 0.97-1.13, P = .21).After subgroup analysis, our study showed that IA might increase the risk of breast cancer in parous women, but in the nulliparous, IA was not significantly associated with an increased risk of breast cancer.

Project description:BackgroundThe aim of our study was to assess the value of serum human epididymis protein 4 (HE4) to diagnose lung cancer and provide reliable scientific conclusions to guide clinical practice.MethodsA systematic search of the PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature, and WANFANG databases was conducted to identify all studies examining serum HE4 in the diagnosis of lung cancer published up to June, 2017. The Quality Assessment of Diagnostic Accuracy Studies tool was used to evaluate the methodological quality of each trial. The meta-analysis was performed using STATA software and Review Manager 5.3.ResultsThere were 21 studies involving 1883 cases and 1696 controls included in our meta-analysis. The pooled sensitivity and specificity of HE4 for diagnosing lung cancer were 0.73 (95% confidence interval [CI] 0.68-0.78) and 0.86 (95% CI 0.81-0.91), respectively. The positive likelihood ratio and negative likelihood ratio were 5.4 (95% CI 3.8-7.5) and 0.31 (95% CI 0.26-0.37), respectively. The diagnostic odds ratio was 17 (95% CI 12-26). The area under the curve of the summary receiver-operating characteristic curve was 0.86 (95% CI 0.83-0.89). Race, assay method, type of cancer, sample size, and publication date might be sources of heterogeneity in our meta-analysis. Subgroup analyses showed that the sensitivity in Caucasians was higher than that in Asians (0.81, 95% CI 0.71-0.91; and 0.71, 95% CI 0.66-0.77, respectively), but the specificity in Asians was better than that in Caucasians (0.87, 95% CI 0.81-0.92; and 0.85, 95% CI 0.73-0.97, respectively). The chemiluminescent microparticle immunoassay had the highest sensitivity, with 0.79 (95% CI 0.73-0.97), and the enzyme-linked immunosorbent assay had the highest specificity, with 0.87 (95% CI 0.79-0.94). HE4 had high diagnostic efficacy when screening for small cell lung cancer with the highest specificity (0.90, 95% CI 0.77-1.00).ConclusionsHE4 is a relatively promising and effective biomarker for the diagnosis of lung cancer. Furthermore, given the limitations of our study, additional large-scale and well-designed studies are needed in the future.

Project description:IntroductionRetinoic acid-induced 2 (RAI2) was initially related to cell differentiation and induced by retinoic acid. RAI2 has been identified as an emerging tumor suppressor in breast cancer and colorectal cancer.MethodsIn this study, we performed systematic analyses of RAI2 in breast cancer. Meta-analysis and Kaplan-Meier survival curves were applied to identify the survival prediction potential of RAI2. Moreover, the association between RAI2 expression and the abundance of six tumor-infiltrating immune cells was investigated by TIMER, including B cells, CD8+ T cells, CD4+ T cells, B cells, dendritic cells, neutrophils, and macrophages. The expression profiles of high and low RAI2 mRNA levels in GSE7390 were compared to identify differentially expressed genes (DEGs) and the biological function of these DEGs was analyzed by R software, which was further proved in GSE7390.ResultsOur results showed that the normal tissues had more RAI2 expression than breast cancer tissues. Patients with high RAI2 expression were related to a favorable prognosis and more immune infiltrates. A total of 209 DEGs and 182 DEGs were identified between the expression profiles of high and low RAI2 mRNA levels in the GSE7390 and GSE21653 databases, respectively. Furthermore, Gene Ontology (GO) enrichment indicated that these DEGs from two datasets were both mainly distributed in "biological processes" (BP), including "organelle fission" and "nuclear division". Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis demonstrated that these DEGs from two datasets were both significantly enriched in the "cell cycle". Common hub genes between the DEGs in GSE7390 and GSE21653 were negatively associated with RAI2 expression, including CCNA2, MAD2L1, MELK, CDC20, and CCNB2.DiscussionsThese results above suggested that RAI2 might play a pivotal role in preventing the initiation and progression of breast cancer. The present study may contribute to understanding the molecular mechanisms of RAI2 and enriching biomarkers to predict patient prognosis in breast cancer.